Skip to content

The REFLECT Study- Flares in axSpA

Evidence Based, Patient-led Development of a Novel Axial Spondyloarthritis Flare Management Pathway

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07688174
Acronym
REFLECT
Enrollment
40
Registered
2026-07-07
Start date
2026-06-01
Completion date
2026-08-31
Last updated
2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Axial Spondylarthritis (r-axSpA), Axial Spondyloarthritis (AxSpA), Axial Spondyloarthritis, Non-Radiographic, Axial Spondyloarthritis, Radiographic

Keywords

flares, flare management, self-management

Brief summary

Axial spondyloarthritis (axSpA) is a long-term inflammatory condition that affects the spine and sacroiliac joints. People living with axSpA often experience periods when their symptoms suddenly worsen, known as disease "flares." These flares can be painful, unpredictable, and significantly affect daily life, work and psychological wellbeing. Their unpredictable nature can leave people feeling helpless and anxious about when symptoms will return. Research has shown that severe or frequent flares are linked to worse long-term outcomes in axSpA. However, it is difficult for researchers and clinicians to clearly define what a flare is, or to predict when one will happen. There is an unmet, urgent need to improve our understanding and recognition of flares, to enable earlier and more effective intervention, and improve long-term outcomes. This study will explore people's experiences of flares, through a real-time digital flare and symptom diary. Data will be captured digitally from people living with axSpA over 12 months, including symptoms, diet, and lifestyle, self-management strategies and impact of flare on life, work, psychological wellbeing and relationships. Participants will attend clinic at two time points only (once when in flare, once when not in flare), to collect blood (serum) samples for investigation of inflammatory markers. Findings will enable us to define and "map" different flare experiences of people living with axSpA and identify windows of opportunity for intervention and effective management. The results will inform the development of a novel, patient-initiated digital pathway for flare identification and management, which will be discussed and refined in a series of workshops with patients and healthcare professionals. This project will take place in two UK NHS hospitals (specialist rheumatology care settings): The Royal National Hospital for Rheumatic Diseases, Bath and King's College Hospital, London. We anticipate future work to pilot test the pathway and inform potential wider NHS implementation

Interventions

None listed

Sponsors

Royal United Hospitals Bath NHS Foundation Trust
Lead SponsorOTHER
Royal National Hospital for Rheumatic Diseases
CollaboratorUNKNOWN
King's College Hospital NHS Trust
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (≥18 years) with a diagnosis of axSpA (non-radiographic or radiographic axSpA). * Access to an email address and electronic device, to participate in data collection. * Capacity to provide informed consent. * Sufficient communicative ability to participate in the research study (must be able to communicate in English). * Patient has experienced at least one (self-reported) flare in the 12-months prior to enrolment.

Exclusion criteria

* Patients \<18 years of age. * Patients with another diagnosis of inflammatory arthritis that is not axial spondyloarthritis. * Living with significant psychiatric morbidity, or if participation may cause distress. * Patient has participated in Project Nightingale (RUH only, 2018 - 2022).

Design outcomes

Primary

MeasureTime frameDescription
Self-reported flaresFrom enrollment to end of 12 monthsTo characterise flare manifestations across the heterogeneous spectrum of axSpA disease and treatments and determine how to most effectively self-manage flare to reduce their impact and duration.

Secondary

MeasureTime frameDescription
Flare management pathway development & refinementFrom the end of the prospective data collection, for 12 monthsTo develop a novel, digitally-facilitated patient-initiated flare management pathway for people living with axSpA.

Countries

United Kingdom

Contacts

PRINCIPAL_INVESTIGATORRaj Sengupta, Professor

Royal National Hospital for Rheumatic Diseases (RNHRD) at the Royal United Hospitals Bath NHS Foundation Trust (RUH)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 8, 2026